Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

Ovarian Cancer Clinical Trial

Official title:

A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in High-Risk Women Using Fenretinide (4-HPR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00098800
• Other study ID #: CDR0000396796
• Secondary ID: P30CA016672UARIZ
• Status: Completed
• Phase: N/A
• First received: December 8, 2004
• Last updated: March 23, 2010
• Start date: October 2004
• Est. completion date: November 2006

Study information

• Verified date: November 2006
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer.

PURPOSE: This randomized clinical trial is studying how well fenretinide works in preventing ovarian cancer in participants who are at high risk of developing ovarian cancer and planning to undergo surgery to remove the ovaries.

Description:

OBJECTIVES:

Primary

• Compare the induction of apoptosis (as determined by TUNEL) in the ovarian epithelial and stromal cells of participants at high risk for ovarian cancer treated with fenretinide vs placebo.

Secondary

• Compare modulation of several intermediate markers (TGFβ, BAX, Ki-67, ER, PR, RARβ, TGFβRI, TGFβRII, p21, p53, FAS, and FASL) in participants treated with these regimens.

• Compare early microvascular changes, using contrast-enhanced ultrasound, in participants treated with these drugs.

• Determine whether the use of contrast agents could indicate changes in ovarian size and architecture that may be assessed as potential surrogates for preventive effect in these participants.

• Determine the feasibility of future chemoprevention trials for ovarian cancer.

• Determine the toxicity of fenretinide in these participants.

• Compare the microvascularity index and ovarian volume of participants treated with these drugs.

• Correlate areas of increased microvascularity and other abnormalities with pathology findings obtained at oophorectomy in participants treated with these drugs.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Participants are randomized to 1 of 2 treatment arms.

• Arm I: Participants receive oral fenretinide once daily.

• Arm II: Participants receive oral placebo once daily. In both arms, treatment continues for 6-8 weeks in the absence of unacceptable toxicity.

Within 5 days after completion of fenretinide or placebo, participants undergo bilateral salpingo-oophorectomy.

Participants are followed at 6 weeks.

PROJECTED ACCRUAL: A total of 40 participants (20 per treatment arm) will be accrued for this study within 4 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: November 2006
• Est. primary completion date: August 2006
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 30 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• At high risk for developing ovarian cancer, meeting 1 of the following criteria:

• Family history of ovarian cancer, defined as = 1 first-degree relative diagnosed with ovarian cancer before 50 years of age

• Family history of ovarian cancer, defined as = 1 first-degree relative diagnosed with ovarian cancer at any age AND = 1 first- or second-degree relative diagnosed with breast or ovarian cancer at any age

• Positive BRCA1/BRCA2 test

• Planning to undergo prophylactic bilateral oophorectomy

PATIENT CHARACTERISTICS:

Age

• 30 and over

Performance status

• Zubrod 0-1

Life expectancy

• At least 12 months

Hematopoietic

• Not specified

Hepatic

• Bilirubin = 1.5 times upper limit of normal (ULN)

• SGOT = 1.5 times ULN

• Alkaline phosphatase = 1.5 times ULN

• No history of liver disease*

• No cholestatic jaundice

• No hepatic adenomas NOTE: *For patients undergoing contrast enhanced ultrasound

Renal

• BUN normal

• Creatinine normal

Cardiovascular

• No history of a congenital heart defect creating a bi-directional or right-to-left shunt*

• No history of congestive heart failure*

• No thrombophlebitis

• No thromboembolic disease

• No cerebral vascular disease

• No coronary artery disease NOTE: *For patients undergoing contrast enhanced ultrasound

Pulmonary

• No history of pulmonary hypertension*

• No history of pulmonary emboli*

• No history of severe emphysema* NOTE: *For patients undergoing contrast enhanced ultrasound

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective barrier contraception

• Thyroid stimulating hormone normal

• T4 normal

• Triglycerides = 1.5 times ULN

• No malignancy within the past 5 years except breast cancer or basal cell or squamous cell skin cancer

• No evidence of recurrent disease

• No known or suspected hypersensitivity to blood, blood products, or albumin

• No undiagnosed genital bleeding

• No history of pancreatitis

• No uncontrolled diabetes

• No other severe underlying chronic disease

• No concurrent alcohol use (> 3 drinks/day or equivalent)

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• At least 3 months since prior chemotherapy for breast cancer

Endocrine therapy

• No concurrent selective estrogen-receptor modulators, including raloxifene

• No concurrent aromatase inhibitors

Radiotherapy

• Not specified

Surgery

• See Disease Characteristics

Other

• More than 3 months since prior therapeutic oral or topical vitamin A derivatives (e.g., isotretinoin)

• No other concurrent investigational agents

• No concurrent cyclooxygenase-2 (COX-2) inhibitors

• No concurrent oral vitamin A or ascorbic acid (vitamin C) supplements > recommended daily requirement (10,000 IU for vitamin A and 75 mg for vitamin C)

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• brca1 Mutation Carrier
• brca2 Mutation Carrier
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• fenretinide

Locations

Country	Name	City	State
United States	Arizona Cancer Center at University of Arizona Health Sciences Center	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
University of Arizona	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States,